ZA200904760B - Multivalent pneumococcal polysaccharide-protein conjugate composition - Google Patents

Multivalent pneumococcal polysaccharide-protein conjugate composition

Info

Publication number
ZA200904760B
ZA200904760B ZA200904760A ZA200904760A ZA200904760B ZA 200904760 B ZA200904760 B ZA 200904760B ZA 200904760 A ZA200904760 A ZA 200904760A ZA 200904760 A ZA200904760 A ZA 200904760A ZA 200904760 B ZA200904760 B ZA 200904760B
Authority
ZA
South Africa
Prior art keywords
polysaccharide
protein conjugate
streptococcus pneumoniae
conjugate composition
pneumococcal polysaccharide
Prior art date
Application number
ZA200904760A
Other languages
English (en)
Inventor
William P Hausdorff
George Rainer Siber
Peter R Paradiso
A Krishna Prasad
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39876611&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200904760(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ZA200904760B publication Critical patent/ZA200904760B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Dry Formation Of Fiberboard And The Like (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200904760A 2006-12-22 2009-07-07 Multivalent pneumococcal polysaccharide-protein conjugate composition ZA200904760B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/644,924 US7709001B2 (en) 2005-04-08 2006-12-22 Multivalent pneumococcal polysaccharide-protein conjugate composition

Publications (1)

Publication Number Publication Date
ZA200904760B true ZA200904760B (en) 2010-04-28

Family

ID=39876611

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200904760A ZA200904760B (en) 2006-12-22 2009-07-07 Multivalent pneumococcal polysaccharide-protein conjugate composition

Country Status (20)

Country Link
US (2) US7709001B2 (cg-RX-API-DMAC10.html)
EP (2) EP2094298B1 (cg-RX-API-DMAC10.html)
JP (1) JP5523836B2 (cg-RX-API-DMAC10.html)
KR (3) KR101511392B1 (cg-RX-API-DMAC10.html)
CN (2) CN101610785B (cg-RX-API-DMAC10.html)
AT (1) ATE545431T1 (cg-RX-API-DMAC10.html)
AU (1) AU2007353769B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0720624A2 (cg-RX-API-DMAC10.html)
CA (1) CA2673477C (cg-RX-API-DMAC10.html)
CL (2) CL2007003782A1 (cg-RX-API-DMAC10.html)
DK (2) DK2094298T3 (cg-RX-API-DMAC10.html)
ES (2) ES2424940T3 (cg-RX-API-DMAC10.html)
IL (2) IL199350A (cg-RX-API-DMAC10.html)
MX (1) MX2009006705A (cg-RX-API-DMAC10.html)
PL (2) PL2094298T3 (cg-RX-API-DMAC10.html)
PT (2) PT2094298E (cg-RX-API-DMAC10.html)
RU (1) RU2493870C2 (cg-RX-API-DMAC10.html)
SI (2) SI2094298T1 (cg-RX-API-DMAC10.html)
WO (1) WO2008143709A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200904760B (cg-RX-API-DMAC10.html)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL308456A (en) 2005-04-08 2024-01-01 Wyeth Llc A multivalent pneumomuroral protein-polysaccharide conjugate preparation
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US20070253985A1 (en) * 2006-04-26 2007-11-01 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
HUE039169T2 (hu) * 2007-03-23 2018-12-28 Wyeth Llc Rövidített tisztítási eljárás Streptococcus pneumoniae tok-poliszacharidok elõállítására
US20110151015A1 (en) * 2008-03-04 2011-06-23 Liquikia Technologies, Inc. Immunomodulator particles and methods of treating
EP2383035A4 (en) 2008-12-03 2017-11-22 Kaneka Corporation Formyl group-containing porous support, adsorbent using same, method for producing same, and method for producing the adsorbent
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
EP2385981B1 (en) * 2008-12-18 2019-09-04 Wyeth LLC Method for controlling streptococcus pneumoniae polysaccharide molecular weight using carbon
WO2010080486A2 (en) 2008-12-18 2010-07-15 Wyeth Llc Method for controlling streptococcus pneumoniae serotype 19a polysaccharide molecular weight
CN104548082A (zh) 2009-03-24 2015-04-29 诺华股份有限公司 为脑膜炎球菌因子h结合蛋白添加佐剂
EP3017826A1 (en) 2009-03-24 2016-05-11 Novartis AG Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
DK2424562T3 (en) 2009-04-30 2015-12-07 Coley Pharm Group Inc Pneumococcal vaccine and uses thereof
WO2011075822A1 (en) 2009-12-22 2011-06-30 Sanofi Pasteur Limited Immunogenic compositions and related methods
US20130209564A1 (en) * 2010-02-22 2013-08-15 Shyam M. Rele Polysaccharide Particle Vaccines
CN101785857B (zh) * 2010-03-05 2012-09-26 成都安特金生物技术有限公司 一种新的肺炎球菌结合疫苗及其制备方法
CN107029223A (zh) 2010-05-26 2017-08-11 西莱克塔生物科技公司 合成纳米载体联合疫苗
EP3626263A1 (en) 2010-06-04 2020-03-25 Wyeth LLC Vaccine formulations
WO2011161653A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
CN102462839B (zh) * 2010-11-12 2016-03-30 北京生物制品研究所 多糖结合疫苗及其制备方法
CN103533954B (zh) 2011-03-02 2015-09-09 诺华股份有限公司 含较低剂量的抗原和/或佐剂的联合疫苗
JP2014521687A (ja) 2011-07-29 2014-08-28 セレクタ バイオサイエンシーズ インコーポレーテッド 体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア
KR101315599B1 (ko) 2011-10-25 2013-10-10 건국대학교 산학협력단 폐렴균점막다당질 유형14 （ｃｐｓ１４）와 호스래디시 퍼옥시다제의 당단백중합체
EP2797624A1 (en) 2011-12-29 2014-11-05 Novartis AG Adjuvanted combinations of meningococcal factor h binding proteins
WO2013131983A1 (en) 2012-03-07 2013-09-12 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
EP2822584A1 (en) 2012-03-08 2015-01-14 Novartis AG Combination vaccines with tlr4 agonists
KR102057217B1 (ko) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
BR112015005056A2 (pt) 2012-09-06 2017-11-21 Novartis Ag vacinas de combinação com sorogrupo b meningococcus e d/t/p
CA2884241C (en) * 2012-09-07 2018-11-20 Sk Chemicals Co., Ltd. Production method for capsular polysaccharide having pneumococcal serotype
KR20140075196A (ko) * 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
JP2016502994A (ja) 2012-12-18 2016-02-01 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ジフテリア及び／又は破傷風から防御するためのコンジュゲート
RU2672053C2 (ru) 2012-12-20 2018-11-09 Пфайзер Инк. Способ гликоконъюгации
US9782468B2 (en) * 2013-05-20 2017-10-10 Shantha Biotechnics Private Limited Purification of polysaccharide protein conjugates
WO2015073831A1 (en) * 2013-11-15 2015-05-21 Liquidia Technologies, Inc. Virtual conjugate particles
IL312327B2 (en) * 2014-01-21 2026-02-01 Pfizer Immunogenic preparations comprising conjugated capsular saccharide antigens and their uses
FI3583947T3 (fi) 2014-01-21 2023-10-12 Pfizer Streptococcus pneumoniaen kapselipolysakkaridit ja niiden konjugaatit
BR112016015835B1 (pt) 2014-01-21 2023-12-26 Pfizer Inc Processo de preparação de conjugados compreendendo polissacarídeos capsulares de streptococcus pneumoniae
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN104069504B (zh) 2014-05-11 2019-09-24 江苏康泰生物医学技术有限公司 一种增强多糖蛋白结合物免疫原性的方法
EP2987408A1 (en) * 2014-08-20 2016-02-24 National University of Ireland, Galway Iodophor composition with improved stability in the presence of organic material
PL3244917T3 (pl) 2015-01-15 2023-07-17 Pfizer Inc. Kompozycje immunogenne do zastosowania w szczepionkach przeciwko pneumokokom
KR102143534B1 (ko) 2015-05-04 2020-08-12 화이자 인코포레이티드 B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도
RS61440B1 (sr) * 2015-06-23 2021-03-31 Biological E Ltd Multivalentna pneumokokna konjugatna vakcina
CN106109486A (zh) * 2015-07-06 2016-11-16 北京科兴中维生物技术有限公司 一种组合物及其制备方法与应用
KR20250058066A (ko) 2015-07-21 2025-04-29 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
EP3359188A1 (en) 2015-10-07 2018-08-15 Boehringer Ingelheim Vetmedica, Inc. Streptococcus suis polysaccharide-protein conjugate composition
US10786561B2 (en) 2015-11-20 2020-09-29 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US11058757B2 (en) 2016-03-31 2021-07-13 Pogona, LLC Saccharide-polypeptide conjugate compositions and methods of use thereof
EP3493837B1 (en) 2016-08-05 2022-08-31 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
US11224652B2 (en) * 2016-08-05 2022-01-18 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
CN109789198B (zh) 2016-09-30 2024-08-16 生物E有限公司 包含多糖-蛋白缀合物的多价肺炎球菌疫苗组合物
WO2018080213A1 (ko) * 2016-10-28 2018-05-03 주식회사 엘지화학 향상된 IgG 역가를 갖는 다가면역원성 조성물 및 이의 용도
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
IL267709B2 (en) 2016-12-30 2025-04-01 Vaxcyte Inc Polypeptide-antigen conjugates with unnatural amino acids
BR112019014833A2 (pt) 2017-01-20 2020-04-14 Pfizer composições imunogênicas para uso em vacinas pneumococais
WO2018144439A1 (en) 2017-01-31 2018-08-09 Merck Sharp & Dohme Corp. Methods for making polysaccharide-protein conjugates
CA3052621A1 (en) 2017-02-03 2018-08-09 Schadeck, Eva Barbara Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof
JP7680185B2 (ja) * 2017-02-24 2025-05-20 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎連鎖球菌多糖－タンパク質コンジュゲートの免疫原性の増強
US11400162B2 (en) * 2017-02-24 2022-08-02 Merck Sharp & Dohme Llc Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein
WO2019050818A1 (en) * 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. METHODS OF FORMULATING PNEUMOCOCCAL POLYSACCHARIDES FOR CONJUGATION TO A CARRIER PROTEIN
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
MX2019014829A (es) * 2017-06-10 2020-08-17 Inventprise Llc Vacunas de conjugado multivalente con polisacáridos de conjugado bivalente o multivalente que proporcionan inmunogenicidad y avidez mejoradas.
WO2019043245A1 (en) * 2017-09-04 2019-03-07 London School Of Hygiene And Tropical Medicine MICROBIAL CELLS EXPRESSING STREPTOCOCCAL SERROTYPES
US11395849B2 (en) * 2017-09-07 2022-07-26 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
CN111065387B (zh) 2017-09-07 2023-08-25 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
HUE068482T2 (hu) 2017-09-07 2025-01-28 Merck Sharp & Dohme Llc Pneumococcus-poliszacharidok és azok felhasználása immunogén poliszacharid-hordozóprotein konjugátumokban
EP3691677A4 (en) 2017-10-04 2021-07-07 Pogona, Llc COMPOSITIONS OF SACCHARIDE-POLYPEPTIDE CONJUGATES AND THEIR METHODS OF USE
EP3720483B1 (en) 2017-12-06 2025-11-19 Merck Sharp & Dohme LLC Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
BR112020015696A2 (pt) 2018-02-05 2020-12-08 Sanofi Pasteur, Inc. Composição de conjugado polissacarídeo-proteína pneumocócico multivalente
WO2019152921A1 (en) * 2018-02-05 2019-08-08 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
TW202011985A (zh) 2018-04-18 2020-04-01 韓商Ｓｋ生物科學股份有限公司 肺炎鏈球菌的莢膜多醣類以及其免疫原性接合體
WO2019212846A1 (en) 2018-04-30 2019-11-07 Merck Sharp & Dohme Corp. Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates
WO2019212842A1 (en) 2018-04-30 2019-11-07 Merck Sharp & Dohme Corp. Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates from lyospheres
JP7397000B2 (ja) 2018-04-30 2023-12-12 メルク・シャープ・アンド・ドーム・エルエルシー 凍結乾燥変異ジフテリア毒素のジメチルスルホキシド中均一溶液を提供する方法
WO2020010016A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Self-adjuvanted immunogenic conjugates
WO2020010000A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Improved methods for the preparation of immunogenic conjugates
EP4483896A3 (en) 2018-07-04 2025-04-02 Vaxcyte, Inc. Improvements in immunogenic conjugates
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
CA3120926A1 (en) 2018-10-12 2020-04-16 Biological E Limited Multivalent pneumococcal polysaccharide-protein conjugate vaccine
US20220016229A1 (en) 2018-12-12 2022-01-20 Pfizer Inc. Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof
EP3897705A2 (en) 2018-12-19 2021-10-27 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
US20220184199A1 (en) 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
JP2022542316A (ja) 2019-07-31 2022-09-30 サノフィ パスツール インコーポレイテッド 多価肺炎球菌多糖体－タンパク質コンジュゲート組成物およびその使用方法
AU2020375214B2 (en) 2019-11-01 2024-02-08 Pfizer Inc. Escherichia coli compositions and methods thereof
KR20220143910A (ko) 2020-02-23 2022-10-25 화이자 인코포레이티드 에스케리키아 콜라이 조성물 및 그의 방법
WO2021229604A1 (en) * 2020-05-14 2021-11-18 Serum Institute Of India Private Limited Methods for simultaneous fragmentation and purification of bacterial polysaccharides
US12053515B2 (en) 2020-08-10 2024-08-06 Inventprise, Inc. Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F
EP4203995A1 (en) 2020-08-26 2023-07-05 Pfizer Inc. Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
MX2023004912A (es) 2020-10-27 2023-05-16 Pfizer Composiciones de escherichia coli y metodos de las mismas.
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
CA3200602A1 (en) 2020-11-04 2022-05-12 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US20230405137A1 (en) 2020-11-10 2023-12-21 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
CA3218544A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
JP7714690B2 (ja) 2021-05-28 2025-07-29 ファイザー・インク コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
CA3221075A1 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
JP2025508749A (ja) 2022-01-13 2025-04-10 ファイザー・インク コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
US20250312433A1 (en) 2022-05-11 2025-10-09 Pfizer Inc. Process for Producing of Vaccine Formulations With Preservatives
US20260130987A1 (en) 2022-10-19 2026-05-14 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
EP4622665A2 (en) 2022-11-22 2025-10-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN120513083A (zh) 2022-12-01 2025-08-19 辉瑞大药厂 肺炎链球菌缀合物疫苗制剂
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2024246082A1 (en) 2023-03-30 2025-10-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP4688877A1 (en) * 2023-04-06 2026-02-11 Vaxcyte, Inc. Purification of capsular polysaccharides
PE20252779A1 (es) 2023-04-14 2025-12-22 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y usos de estos
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN121263203A (zh) 2023-05-19 2026-01-02 葛兰素史克生物有限公司 诱导对呼吸道合胞病毒和肺炎链球菌感染的免疫反应的方法
TW202527906A (zh) 2023-09-14 2025-07-16 美商輝瑞股份有限公司 包含經結合之肺炎鏈球菌莢膜醣抗原之佐劑化致免疫性組成物及其用途
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
US20250255948A1 (en) 2024-02-14 2025-08-14 Merck Sharp & Dohme Llc Pneumococcal conjugate vaccines and methods of use thereof
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
TW202602467A (zh) 2024-03-11 2026-01-16 美商輝瑞股份有限公司 包含經共軛之大腸桿菌糖的免疫原性組成物及其用途
WO2025219904A1 (en) 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3926258A (en) * 1972-12-27 1975-12-16 Phillips Petroleum Co Method for reducing formation permeability with gelled polymer solution having delayed gel time
US4097666A (en) * 1976-04-29 1978-06-27 The Institute Of Paper Chemistry Solvent system for polysaccharides
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US5097020A (en) * 1983-07-05 1992-03-17 The University Of Rochester Immunogenic conjugates
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US5110908A (en) 1986-12-31 1992-05-05 Praxis Biologics, Inc. Haemophilus influenzae peptides and proteins
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DE69012318T2 (de) 1989-03-09 1995-03-09 Praxis Biologics, Inc., Rochester, N.Y. Impfstoffe gegen hämophilus influenzae.
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
WO1993013302A1 (de) 1991-12-23 1993-07-08 Michael Zoche Motor mit einer vorrichtung zur entölung
JPH0698749A (ja) * 1992-09-21 1994-04-12 Sapporo Breweries Ltd 高発酵度ビールの製造方法
DK0616034T3 (da) 1993-03-05 2005-02-21 Wyeth Corp Plasmid til fremstilling af CRM-protein og diphtheria toxin
US5712118A (en) 1993-09-29 1998-01-27 Research Foundation Of State University Of New York Vaccine for branhamella catarrhalis
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
US5770213A (en) 1994-05-05 1998-06-23 American Cyanamid Company Purified nontypable haemophilus influenzae P5 protein as a vaccine for nontypable haemophilus influenzae infection
US5607846A (en) 1994-05-17 1997-03-04 Research Foundation Of State University Of New York Vaccine for moraxella catarrhalis
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5643725A (en) 1994-07-19 1997-07-01 American Cyanamid Company Sequence and analysis of LKP pilin structural genes and the LKP pili operon of nontypable haemophilus influenzae
US6245337B1 (en) 1994-08-25 2001-06-12 Washington University Haemophilus adherence and penetration proteins
US6676948B2 (en) 1994-08-25 2004-01-13 Washington University Haemophilus adherence and penetration proteins
DE4432899A1 (de) * 1994-09-15 1996-03-21 Wacker Chemie Gmbh Vernetzbare Polymerpulver-Zusammensetzungen
US5811102A (en) * 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
ATE277182T1 (de) 1996-07-26 2004-10-15 Wyeth Corp Das nuca protein von haemophilus influenzae und dessen kodierender gen
DE69740108D1 (de) 1996-12-20 2011-03-10 Univ Texas Moraxella catarrhalis antigene uspa1 und uspa2
AU747479B2 (en) 1997-01-31 2002-05-16 Wyeth Holdings Corporation The 74 kilodalton outer membrane protein from (moraxella catarrhalis)
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
AU761784B2 (en) * 1997-12-09 2003-06-12 Biomedical Frontiers, Inc. Modified polysaccharides exhibiting altered biological recognition
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
EP1115875A1 (en) 1998-09-24 2001-07-18 Regents Of The University Of Minnesota Human complement c3-degrading polypeptide from streptococcus pneumoniae
JP4673974B2 (ja) 1998-09-30 2011-04-20 ワイス・ホールディングズ・コーポレイション アジュバントとしての変異コレラホロトキシン
EP1034792A1 (en) * 1999-03-11 2000-09-13 Pasteur Merieux Serums Et Vaccins Intranasal delivery of pneumococcal polysaccharide vaccines
EP1035137A1 (en) 1999-03-12 2000-09-13 Pasteur Merieux Serums Et Vaccins Method for the reductive amination of polysaccharides
CA2366152A1 (en) * 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Streptococcus pneumoniae vaccine
KR100283848B1 (ko) * 1999-03-19 2001-02-15 서경배 안정화된 효소 또는 단백질을 제조하는 방법 및 이에 의해 제공되는 안정화 효소 또는 단백질을 함유하는 외용제 조성물
EP1192242B1 (en) 1999-06-25 2010-05-05 Wyeth Holdings Corporation Production of the lipidated form of the peptidoglycan-associated lipoproteins of gram-negative bacteria
KR20080081978A (ko) * 2000-03-16 2008-09-10 더 칠드런스 호스피탈 오브 필라델피아 폐렴구균의 캡슐 다당류 생산의 조절 방법
GB0011108D0 (en) 2000-05-08 2000-06-28 Microscience Ltd Virulence gene and protein and their use
GB0012079D0 (en) 2000-05-18 2000-07-12 Microscience Ltd Virulence gene and protein, and their use
EP1946769B1 (en) * 2000-06-29 2012-05-30 SmithKline Beecham Biologicals S.A. Multivalent vaccine composition with reduced dose of Haemophilus influenzae type B
GB0020952D0 (en) 2000-08-24 2000-10-11 Microscience Ltd Genes and proteins and their uses
EP1341717B1 (en) * 2000-12-13 2004-05-26 SCA Hygiene Products Zeist B.V. Recovery process for spent periodate
BR0116756A (pt) 2000-12-28 2005-01-04 Wyeth Corp Proteìna protetora recombinante de streptococcus pneumoniae e uso da mesma
KR100886095B1 (ko) 2001-04-16 2009-02-27 와이어쓰 홀딩스 코포레이션 폴리펩티드 항원을 암호화하는 신규한 스트렙토코쿠스 뉴모니애 개방형 판독 프레임 및 이를 포함하는 조성물
WO2002098368A2 (en) 2001-06-07 2002-12-12 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
US7332174B2 (en) 2001-06-07 2008-02-19 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US20050203280A1 (en) 2001-11-29 2005-09-15 Mcmichael John C. Alloiococcus otitidis open reading frames (orfs) encoding polypeptide antigens, immunogenic compositions and uses thereof
GB0130215D0 (en) 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
CA2479118A1 (en) 2002-03-15 2003-09-25 Wyeth Holdings Corporation Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
WO2003094961A1 (en) * 2002-05-09 2003-11-20 Massimo Porro Improved polysaccharide and glycoconjugate vaccines_____________
US20040096461A1 (en) * 2002-07-30 2004-05-20 Baxter Healthcare Corporation Chimeric multivalent polysaccharide conjugate vaccines
US20060121058A1 (en) * 2002-08-08 2006-06-08 Children's Medical Center Corporation Anti-pneumococcal preparations
WO2004026024A2 (en) * 2002-09-20 2004-04-01 The United States Of America As Represented By The Secretary Of Agriculture Vaccine compositions and adjuvant
FR2850106B1 (fr) 2003-01-17 2005-02-25 Aventis Pasteur Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5
EP1603950A2 (en) 2003-03-17 2005-12-14 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
BRPI0409459A (pt) 2003-04-16 2006-05-02 Wyeth Corp novas composições imunogênicas para a prevenção e tratamento de doença meningocócica
CN1241937C (zh) * 2003-07-04 2006-02-15 上海健益科技发展有限公司 多价肺炎球菌多糖结合疫苗
AU2004263135B2 (en) * 2003-08-06 2010-11-25 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
EP1664319B1 (en) * 2003-09-11 2010-03-10 De Staat der Nederlanden, vert. door de minister van VWS Process for producing a capsular polysaccharide for use in conjugate vaccines
FR2857364B1 (fr) 2003-12-08 2005-09-23 Aventis Pasteur Dosage des acides techoiques des bacteries gram+
SG149013A1 (en) 2003-12-17 2009-01-29 Wyeth Corp Immunogenic peptide carrier conjugates and methods of producing same
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
IL308456A (en) * 2005-04-08 2024-01-01 Wyeth Llc A multivalent pneumomuroral protein-polysaccharide conjugate preparation
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition

Also Published As

Publication number Publication date
JP2010513549A (ja) 2010-04-30
ATE545431T1 (de) 2012-03-15
KR101700837B1 (ko) 2017-02-01
US20100316666A1 (en) 2010-12-16
IL222793A (en) 2015-08-31
EP2094298B1 (en) 2012-02-15
ES2379834T3 (es) 2012-05-04
IL199350A (en) 2013-05-30
DK2094298T3 (da) 2012-03-26
AU2007353769A1 (en) 2008-11-27
CA2673477C (en) 2013-09-10
SI2417983T1 (sl) 2013-09-30
KR101511392B1 (ko) 2015-04-13
PL2417983T3 (pl) 2013-10-31
KR20150140411A (ko) 2015-12-15
WO2008143709A3 (en) 2009-01-08
DK2417983T3 (da) 2013-08-26
KR20090096731A (ko) 2009-09-14
CA2673477A1 (en) 2008-11-27
CN103599529A (zh) 2014-02-26
KR20140130567A (ko) 2014-11-10
AU2007353769B2 (en) 2013-01-10
IL222793A0 (en) 2012-12-31
JP5523836B2 (ja) 2014-06-18
RU2009125216A (ru) 2011-01-27
RU2493870C2 (ru) 2013-09-27
US7709001B2 (en) 2010-05-04
CL2007003782A1 (es) 2009-01-16
IL199350A0 (en) 2010-03-28
HK1191567A1 (zh) 2014-08-01
PL2094298T3 (pl) 2012-06-29
US20070231340A1 (en) 2007-10-04
CN103599529B (zh) 2016-03-16
EP2417983A1 (en) 2012-02-15
ES2424940T3 (es) 2013-10-10
US8603484B2 (en) 2013-12-10
EP2417983B1 (en) 2013-06-26
SI2094298T1 (sl) 2012-04-30
WO2008143709A2 (en) 2008-11-27
CN101610785A (zh) 2009-12-23
BRPI0720624A2 (pt) 2014-03-25
PT2417983E (pt) 2013-08-26
EP2094298A2 (en) 2009-09-02
CN101610785B (zh) 2013-11-27
CL2017001842A1 (es) 2018-05-04
PT2094298E (pt) 2012-04-03
MX2009006705A (es) 2009-06-30

Similar Documents

Publication Publication Date Title
IL222793A0 (en) Multivalent pneumococcal polysaccharide - protein conjugate composition
IL186367A (en) A conjugate compound of multi-value polyneural polysaccharide protein
MX2009006548A (es) Composicion conjugada polisacarido-proteina neumococica multivalente.
WO2008079732A3 (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
TN2012000377A1 (en) 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
WO2007071707A3 (en) Pneumococcal polysaccharide conjugate vaccine
MX2009013949A (es) Vacuna que comprende conjugados de polisacárido capsular de streptococcus pneumoniae.
PH12015501269A1 (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
PH12015501270A1 (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
JP2010513549A5 (cg-RX-API-DMAC10.html)